April 11, 2019 / 5:19 AM / 14 days ago

BRIEF-Novartis' Sandoz Strikes Deal To Commercialize Constipation Treatment

April 11 (Reuters) - Novartis AG:

* SANDOZ DRIVES DIFFERENTIATED PORTFOLIO WITH DEAL TO COMMERCIALIZE NEW TREATMENT FOR OPIOID-INDUCED CONSTIPATION IN KEY EUROPEAN COUNTRIES

* AGREEMENT WITH SHIONOGI TO COMMERCIALIZE RIZMOIC® (NALDEMEDINE) IN GERMANY, UK AND NETHERLANDS, PLUS RIGHT OF FIRST REFUSAL FOR CERTAIN OTHER EUROPEAN MARKETS Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below